A weight loss study evaluating subcutaneous treatment withAZD9550 and AZD6234 in combination, against placebo or each of the drugs alone

Prior treatment

• History of major depressive disorder within the 2 years prior to screening or depression.
• Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the3 months or 5 half-lives of the drug prior to screening
• Previous or planned bariatric surgery or fitting of a weight loss device.

Other illness

• History of any clinically important disease or disorder, which, in the opinion of the Investigator
• History or presence of GI, renal, hepatic disease
• Obesity induced by endocrine disorders such as Cushing’s syndrome, insulinoma or Prader-Willi syndrome.
• Significant gastric and hepatobiliary disease
• History of psychosis or bipolar disorder.

Lab values

• History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control.
• HbA1c≥ 6.5% (48 mmol/mol), fasting serum glucose≥126 mg/dL(7.0 mmol/L) or random glucose≥200 mg/dL (11.1 mmol/L).
• History of acute or chronic pancreatitis or pancreatic amylase or lipase > 2 × ULN at screening.

Other

• Vulnerable populations

• Participant must be 18 to 75 years of age inclusive
• BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity
• A stable, self-reported body weight for 3 months prior to screening
• Male and female participants: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline
• Capable of giving signed informed consent